Clinical Trials Logo

Scleroderma Disease clinical trials

View clinical trials related to Scleroderma Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT03388255 Terminated - Scleroderma Disease Clinical Trials

Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases

Start date: November 8, 2016
Phase: Phase 4
Study type: Interventional

This is a phase IV, single-arm, open-label clinical trial to evaluate the efficacy and safety of PLACENTEX ® Polydeoxyribonucleotide i.m. in patients with fibrotic and atrophic cutaneous lesions in scleroderma diseases during the inactive stage of the disease (experiencing dystrophic outcomes of the disease with no inflammatory component at the time of enrolment). The patients enrolled will be evaluated at study site at screening (V1), then after 3 months of treatment with PLACENTEX ® Polydeoxyribonucleotide (one vial per day for intra-muscular administration) (V2). After completion of the study treatment period, the patients will be followed for an additional period of 3 months without study medication, after which the patient will visit the site for the last visit (V3). 1 investigational site. 45 patients enrolled (included drop-outs).3 months of treatment with PLACENTEX ® Polydeoxyribonucleotide (one vial per day for intra-muscular administration).